IMPACT-AD will help Canadians develop a comprehensive understanding
of how Alzheimer’s disease biomarker testing impacts medical and
personal decision making, and health care costs. The goal of IMPACT-AD is to
inform positive change in the Canadian health care system to improve care and
support for individuals living with Alzheimer’s disease, and their families.
Alzheimer’s disease causes progressive neurological decline and decreases the quality of life of the individuals with the disease and their caregivers. Today there are over half a million Canadians living with Alzheimer’s disease or a related form of dementia. With a rapidly aging population, both the number of Canadians with dementia and associated costs (currently $10.4 billion per year) are projected to double by 2031, representing an urgent and rapidly growing health care issue.
Early and accurate diagnosis of Alzheimer’s disease is critical because timely access to health care and community services has the potential to lead to more effective treatment and improve quality of life. Current approaches for diagnosis rely on imaging tests and observation of the signs and symptoms of the disease. Adding the measure of proteins found in cerebrospinal fluid (biomarkers) has been shown to help correctly identify the disease and predict those with mild symptoms that are likely to progress to dementia.
ROLE OF IMPACT-AD
IMPACT-AD will help Canadians develop a comprehensive understanding of how Alzheimer’s disease biomarker testing impacts medical and personal decision making, and health care costs. The objective of IMPACT-AD is to inform positive change in the Canadian health care system to improve care and support for individuals living with Alzheimer’s disease, and their families.
WHAT IS A BIOMARKER?
A biomarker is a substance found in the body that is an indicator of the presence of a particular disease.
WHAT IS ALZHEIMER'S DISEASE BIOMARKER TESTING?
For individuals with cognitive complaints (e.g. memory concerns) testing for two biomarkers – amyloid-beta and tau – improves the ability of doctors to correctly identify the underlying disease. Measuring these two biomarkers in the fluid surrounding the brain (i.e. cerebrospinal fluid) helps doctors identify whether the cause of the cognitive difficulties is due to Alzheimer’s disease.
WHAT ARE THE BENEFITS OF EARLY DIAGNOSIS?
“Knowing what you face helps with planning, getting the right medication, care and support. It also helps you and your family prepare for the road ahead.” - Alzheimer Society of Canada
For more information visit: http://www.earlydiagnosis.ca/
WHAT DO I GAIN BY PARTICIPATING IN IMPACT-AD?
Participants in IMAPCT-AD will be given the results of their Alzheimer’s disease biomarker test. Your study doctor will provide your test results, discuss their meaning and answer any questions you might have.
HOW CAN I PARTICIPATE IN IMPACT-AD?
IMPACT-AD has partnered with the COMPASS-ND study, which has participation sites in 12 cities across Canada. To get more information about participating in COMPASS-ND contact Victor Whitehead (Victor.Whitehead@ladydavis.ca).
WHERE ARE PARTICIPATION SITES LOCATED?
Vancouver, Prince George, Calgary, Edmonton, London, Kitchener/Waterloo, Toronto, Peterborough, Ottawa, Montreal, Quebec City and St. John
WHAT IS COMPASS-ND?
The COMPASS-ND (Comprehensive Assessment of Neurodegeneration and Dementia) study is an observational study of people with various types of cognitive complaints. The study collects clinical, neuropsychological, and imaging data as well as blood, saliva, and urine samples from participants. Participants who consent to a lumbar puncture to collect a sample of cerebrospinal fluid can participate in IMPACT-AD.
Mari DeMarco, PhDPrincipal Investigator
Howard Feldman, MDTrial Design Lead
Robin Hsiung, MDBiomarker Team
Jason Karlawish, MDPersonal Utility Lead
John Best, PhDStatistical Lead
Howard Chertkow, MDBiomarker Team
Shana Stites, PsyDPersonal Utility Team
Serge Gauthier, MDPersonal Utility Team
Jacqueline Pettersen, MDRural & Remote Health Lead
Haakon Nygaard, MDBiomarker Team